MS Mission Possible Logo


Physical Activity
Diet & Nutrition
Healthy Living
Medical Resources
Family & Friends
MS News
Contact Us

MS News

FDA Approves Botox® for Treating Urinary Incontinence in MS and other Neurologic Conditions

Aug 30, 2011
A new use for Botox® (onabotulinumtoxin A, Allergan, Inc.) was approved by the FDA, providing an additional treatment option for people with MS or other neurologic disorders who experience urinary incontinence.

Information from Medtronic about possible battery issues in Synchromed® drug pumps

Aug 15, 2011
In July, Medtronic provided physicians with new information about possible reduced battery performance in a small percentage of the SynchroMed® drug pumps used to deliver intrathecal baclofen, a medication used to treat severe spasticity. A battery with reduced performance may need to be replaced sooner than expected. In addition, the reduced performance may cause the drug flow rate to be reset to a very low level. In the event of reduced battery performance, a person would experience a significant increase in spasticity or and perhaps some withdrawal symptoms as the supply of medication is decreased. Medtronic is NOT recommending pump replacement because the risk of this change in battery performance is very low, and the surgery poses its own risks. The pump’s alarm system will sound if there is a problem. Read here for more information.

FDA issues warning about medications containing oxybutynin

Jul 15, 2011
Some of medications (Ditropan®, Ditropan XL®, Gelnique® gel, Oxytrol® transdermal patch) used to treat urinary problems in people with MS contain oxybutynin. The FDA has added a warning to the labeling of these medications stating that angioedema (a swelling similar to hives that occurs under the skin) of the face, lips, tongue and/or larynx has been reported with oxybutynin taken orally.

Multiple Sclerosis Emerging Therapies Collaborative - UPDATE

Jun 17, 2011
We are proud to announce the launch of the Multiple Sclerosis Emerging Therapies Collaborative. The Collaborative – which includes the members of the MS Coalition, the American Academy of Neurology, and the VA Multiple Sclerosis Centers of Excellence East and West – has as its mission:

UPDATE on Tysabri and PML

Apr 11, 2011
According to information released by Biogen Idec, as of August 4, 2011, there have been 150 confirmed cases of PML among people who have used Tysabri after it became available for prescription in July 2006. Further details about risks are provided here.